TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10706957

Group type: EXPERIMENTAL
Intervention: Bicomponent acellular vaccine (pertussis toxin and filamentous hemagglutinin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monocomponent acellular vaccine (pertactin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls (no vaccination)
Number of subjects: 0
Study: 9305674

Group type: COMPARATOR
Intervention: Ribavirin alone for 24 to 48 weeks
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ribavirin combined with alpha interferon (3 million units three times weekly for 6 months)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Alpha interferon alone
Number of subjects: 150
Study: 1588426

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 168
Study: 3904040

Group type: EXPERIMENTAL
Intervention: Lasix
Number of subjects: 12

Group type: COMPARATOR
Intervention: Aquasin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Puresis
Number of subjects: 12

Group type: COMPARATOR
Intervention: Furetic
Number of subjects: 12
Study: 29253747

Group type: COMPARATOR
Intervention: 15 mg/kg/d of methylprednisolone (group T1, n=17)
Number of subjects: 51

Group type: COMPARATOR
Intervention: 15 mg/kg/d of methylprednisolone at consent and 100 mg/2 h until kidney harvest (group T2, n=17)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Normal donors as controls (n=17)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Kidney recipients from group T1
Number of subjects: 51
Study: 29092730

Group type: EXPERIMENTAL
Intervention: Clopidogrel generic 75 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Clopidogrel reference 75 mg
Number of subjects: 20
Study: 26651616

Group type: EXPERIMENTAL
Intervention: Game (serious game format)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control (non-interactive webpage)
Number of subjects: 182
Study: 23447407

Group type: EXPERIMENTAL
Intervention: FTC/TDF alone for 72 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: FTC/TDF plus HBIG for 72 weeks
Number of subjects: 40
Study: 21034301

Group type: EXPERIMENTAL
Intervention: Fear-related pictures
Number of subjects: 63

Group type: COMPARATOR
Intervention: Neutral pictures
Number of subjects: 63
Study: 18706802

Group type: EXPERIMENTAL
Intervention: ropivacaine with sufentanil 5 microg
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: ropivacaine with clonidine 75 microg
Number of subjects: 78

Group type: COMPARATOR
Intervention: plain ropivacaine
Number of subjects: 78
Study: 16539572

Group type: EXPERIMENTAL
Intervention: Motivational enhancement intervention (4 sessions)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 51
Study: 12752561

Group type: EXPERIMENTAL
Intervention: Postural sway measurement using Balance Master Pro(R)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Postural sway measurement with respect to body weight and alcohol consumption
Number of subjects: 195
Study: 10578207

Group type: EXPERIMENTAL
Intervention: High-protein diet (HP; 25 E% protein)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Low-protein diet (LP; 12 E% protein)
Number of subjects: 65
Study: 8566257

Group type: EXPERIMENTAL
Intervention: Oral micronized E2
Number of subjects: 27

Group type: COMPARATOR
Intervention: Transdermal E2
Number of subjects: 27
Study: 1662191

Group type: EXPERIMENTAL
Intervention: ITRA-PEL (2 x 100 mg once daily)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ITRA-PEG (4 x 50 mg once daily)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Comparison of ITRA-PEL and ITRA-PEG
Number of subjects: 8
Study: 7102528

Group type: EXPERIMENTAL
Intervention: Pindolol 5 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pindolol 10 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pindolol 20 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31356432

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (ABO) 50 Units
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 30520216

Group type: EXPERIMENTAL
Intervention: Whey/guar preload (150 mL containing 17 g whey protein plus 5 g guar)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo preload
Number of subjects: 79
Study: 26598291

Group type: EXPERIMENTAL
Intervention: Intimate Partner Violence (IPV)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Maternal corporal punishment/physical violence
Number of subjects: 400

Group type: COMPARATOR
Intervention: Maternal depression and attitudes about corporal punishment
Number of subjects: 400

Group type: COMPARATOR
Intervention: Non-use of corporal punishment/physical violence
Number of subjects: 400
Study: 27129183

Group type: EXPERIMENTAL
Intervention: Colchicine (1 mg followed by 0.5 mg 1 hour later)
Number of subjects: 21

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 21
Study: 24472156

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL) dispersible
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP) paediatric tablets
Number of subjects: 454
Study: 22948132

Group type: EXPERIMENTAL
Intervention: Cabergoline 0.25mg for 8 days from the day of HCG administration
Number of subjects: 200

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 200
Study: 20718766

Group type: EXPERIMENTAL
Intervention: r-hPRL (60 μg/kg) administered subcutaneously every 12 h for 28 days (Study 1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: r-hPRL (60 μg/kg) administered every 12 h for 7 days (Study 2)
Number of subjects: 16

Group type: COMPARATOR
Intervention: r-hPRL (60 μg/kg) administered daily for 7 days (Study 2)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo administered for 7 days (Study 2)
Number of subjects: 16

Group type: COMPARATOR
Intervention: r-hPRL alternating with placebo every 12 h for 7 days (Study 2)
Number of subjects: 16
Study: 17951067

Group type: EXPERIMENTAL
Intervention: 4 g/d curcumin
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 1 g/d curcumin
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 15664003

Group type: EXPERIMENTAL
Intervention: Menatetrenone (MK-4) 45 mg, ergocalciferol (vitamin D2) 1000 IU, calcium 600 mg daily for 2 years
Number of subjects: 200

Group type: COMPARATOR
Intervention: Untreated group (no intervention)
Number of subjects: 200
Study: 14717246

Group type: EXPERIMENTAL
Intervention: Learning nouns in the context of novel, moving objects
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Learning verbs
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Familiar objects for child verb learners
Number of subjects: 72

Group type: COMPARATOR
Intervention: Adults (N = 20) learning verbs
Number of subjects: 72
Study: 10067809

Group type: EXPERIMENTAL
Intervention: Low-fat, high-carbohydrate diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduction in total or saturated fat intake or cholesterol intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduction in dietary cholesterol intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduction in saturated fat intake
Number of subjects: 0
Study: 7726651

Group type: EXPERIMENTAL
Intervention: 1 mg gemeprost (Cergem)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Conventional surgical termination of pregnancy by cervical dilatation and curettage
Number of subjects: 87
Study: 2024813

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg/day for 3 days)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 6788167

Group type: EXPERIMENTAL
Intervention: Biofeedback group receiving training in relaxation and management of stress
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group receiving simple health education literature
Number of subjects: 204
Study: 31133577

Group type: EXPERIMENTAL
Intervention: SAFE+support as usual
Number of subjects: 0

Group type: COMPARATOR
Intervention: Support as usual alone
Number of subjects: 0
Study: 28132019

Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine
Number of subjects: 21596

Group type: COMPARATOR
Intervention: Control arm (no vaccination)
Number of subjects: 21596
Study: 24942311

Group type: EXPERIMENTAL
Intervention: Nitric oxide supplementation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 23688777

Group type: EXPERIMENTAL
Intervention: Maximal isokinetic eccentric exercise (EE) muscle damage protocol (5×15) of the knee extensors and flexors at 60°/s
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Controlled walking speed during COND2 (±5% of pre-EE speed)
Number of subjects: 15
Study: 21308360

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (130/0.4)
Number of subjects: 7000

Group type: COMPARATOR
Intervention: 0.9% sodium chloride (saline)
Number of subjects: 7000
Study: 19614965

Group type: EXPERIMENTAL
Intervention: Prednisolone (150 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 18001616

Group type: EXPERIMENTAL
Intervention: Atorvastatin therapy
Number of subjects: 0
Study: 14688699

Group type: EXPERIMENTAL
Intervention: Enoxaparin 1 mg/kg twice daily (n = 21)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Intravenous heparin (n = 20)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (n = 23)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 64
Study: 14635283

Group type: EXPERIMENTAL
Intervention: Modified dance-based exercise program (8 weeks)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Locomotion biomechanical analysis
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 6-minute gait test
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 50-foot gait test
Number of subjects: 10
Study: 8825016

Group type: EXPERIMENTAL
Intervention: Ocuguard (broad spectrum antioxidant capsule)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 1373372

Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 3900361

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Behaviour therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group psychotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 60
Study: 3696105

Group type: EXPERIMENTAL
Intervention: Carboxyhemoglobin levels of 16-23%
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (n = 23)
Number of subjects: 18
Study: 29505553

Group type: EXPERIMENTAL
Intervention: Steato‐ELSA
Number of subjects: 9857

Group type: EXPERIMENTAL
Intervention: Fatty Liver Index
Number of subjects: 9857

Group type: EXPERIMENTAL
Intervention: Hepatic Steatosis Index
Number of subjects: 9857

Group type: EXPERIMENTAL
Intervention: Nonalcoholic Fatty Liver Disease‐Liver Fat Score
Number of subjects: 9857
Study: 29558987

Group type: EXPERIMENTAL
Intervention: Voucher scheme to promote physical activity
Number of subjects: 78
Study: 28566688

Group type: EXPERIMENTAL
Intervention: Low-dose HDM specific sublingual immunotherapy (n = 29)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: High-dose HDM specific sublingual immunotherapy (n = 26)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo (n = 22)
Number of subjects: 77
Study: 26187555

Group type: EXPERIMENTAL
Intervention: Interferon-based therapy for 12 weeks
Number of subjects: 1441
Study: 24107662

Group type: EXPERIMENTAL
Intervention: Desflurane 4‐6% (Group D)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sevoflurane 1‐2% (Group S)
Number of subjects: 56
Study: 20604775

Group type: EXPERIMENTAL
Intervention: Liquid-based cytology (LBC) in NETHCON
Number of subjects: 139218

Group type: COMPARATOR
Intervention: Conventional cytology (CC) in NETHCON
Number of subjects: 139218

Group type: EXPERIMENTAL
Intervention: Liquid-based cytology (LBC) in NTCC
Number of subjects: 139218

Group type: COMPARATOR
Intervention: Conventional cytology (CC) in NTCC
Number of subjects: 139218
Study: 18472200

Group type: EXPERIMENTAL
Intervention: Psycho-education programs targeting both couple relationship and parenting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psycho-education programs targeting couple relationship
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psycho-education programs targeting parenting
Number of subjects: 0
Study: 16700881

Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Furosemide (20 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: ACEI (imidapril 5 mg/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ACEI (imidapril 5 mg/day) + Spironolactone (25 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: ACEI (imidapril 5 mg/day) + Furosemide (20 mg/day)
Number of subjects: 30
Study: 12699450

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (Genotropin, 0.8 IU daily for 1 month, then 1.6 IU daily for 5 months)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 10781127

Group type: EXPERIMENTAL
Intervention: Tracheal intubation in glaucomatous children
Number of subjects: 35

Group type: COMPARATOR
Intervention: Tracheal intubation in normal children
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Tracheal extubation in glaucomatous children
Number of subjects: 35

Group type: COMPARATOR
Intervention: Tracheal extubation in normal children
Number of subjects: 35
Study: 8638600

Group type: EXPERIMENTAL
Intervention: Burstone‐type intrusion arch delivering low level of force (about 15 gm per tooth)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Full‐arch fixed appliances (control group)
Number of subjects: 17
Study: 1465036

Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (sCT) 200 IU/day, continuous regimen for 2 years
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (sCT) 200 IU/day, cyclic regimen (3 months on, 1 month off) for 2 years
Number of subjects: 48

Group type: COMPARATOR
Intervention: Calcium supplementation alone (500 mg/day)
Number of subjects: 48
Study: 6146570

Group type: COMPARATOR
Intervention: 6-month exercise training programme (5BX/XBX)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Long-term maintenance training (up to 4.5 years)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Long-term maintenance training in patients on beta-blocker therapy
Number of subjects: 17
Study: 29589419

Group type: EXPERIMENTAL
Intervention: Flexed neck position
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Extended neck position
Number of subjects: 39

Group type: COMPARATOR
Intervention: Neutral position
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Right rotated head and neck position
Number of subjects: 39
Study: 29176359

Group type: EXPERIMENTAL
Intervention: Virtual intravenous simulator
Number of subjects: 65

Group type: COMPARATOR
Intervention: Plastic arm model
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group symptoms
Number of subjects: 65
Study: 26669692

Group type: EXPERIMENTAL
Intervention: Computerized working memory training (CWMT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo training
Number of subjects: 66
Study: 25304939

Group type: EXPERIMENTAL
Intervention: Practicing two procedures (an appendectomy followed by a salpingectomy)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Practicing only one procedure (a salpingectomy)
Number of subjects: 96
Study: 22067902

Group type: EXPERIMENTAL
Intervention: Ibandronate 150 mg oral monthly
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 20499222

Group type: EXPERIMENTAL
Intervention: Ultrasound imaging for lumbar spinous process identification
Number of subjects: 74
Study: 18497717

Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy for Substance Abusers (DBT-SAB)
Number of subjects: 0
Study: 15891919

Group type: EXPERIMENTAL
Intervention: Dual-chamber rate-modulated pacing
Number of subjects: 23

Group type: COMPARATOR
Intervention: Ventricular pacing
Number of subjects: 23
Study: 11792604

Group type: EXPERIMENTAL
Intervention: Oral ibandronate (doses: 0.25, 0.50, 1.0, 2.5, or 5.0 mg daily)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Oral ibandronate
Number of subjects: 180
Study: 11012955

Group type: EXPERIMENTAL
Intervention: Sedation protocol with rectal midazolam (0.5 mg x kg(‐1)) and S‐(+)‐ketamine (5 mg x kg(‐1)) plus i.v. supplementation (20+/‐10 microg x kg(‐1) x min(‐1) S‐(+)‐ketamine and 4+/‐2 microg x kg(‐1) x min(‐1) midazolam)
Number of subjects: 34

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 34
Study: 8787886

Group type: EXPERIMENTAL
Intervention: 200 mg genaconazole (racemate)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100 mg or 200 mg genaconazole (RR enantiomer)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 50 mg of 14C-labeled genaconazole
Number of subjects: 12
Study: 1449110

Group type: EXPERIMENTAL
Intervention: 2'-deoxycoformycin (dCF) alone
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Combination of 2'-deoxycoformycin (dCF) and adenine arabinoside (ara-A)
Number of subjects: 49
Study: 4016828

Group type: EXPERIMENTAL
Intervention: Wax-matrix iron preparation
Number of subjects: 181

Group type: COMPARATOR
Intervention: Sustained-release iron preparation
Number of subjects: 181
Study: 31066079

Group type: EXPERIMENTAL
Intervention: Novel matching algorithms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current matching algorithms
Number of subjects: 0
Study: 29027815

Group type: EXPERIMENTAL
Intervention: l‐carnosine (800 mg/day in 2 divided doses)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 27411697

Group type: EXPERIMENTAL
Intervention: Development of type 2 diabetes
Number of subjects: 542

Group type: COMPARATOR
Intervention: Before development of type 2 diabetes
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: After development of type 2 diabetes
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Cumulative mortality in participants who developed type 2 diabetes in first 10 years
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Cumulative mortality in participants who progressed to type 2 diabetes in 10-20 years
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Cumulative mortality in those who did not develop type 2 diabetes within 20 years
Number of subjects: 542
Study: 23379386

Group type: EXPERIMENTAL
Intervention: Strong African American Families‐Teen (SAAF‐T) program
Number of subjects: 502

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 502

Group type: COMPARATOR
Intervention: SAAF‐T and Control condition
Number of subjects: 502
Study: 23924044

Group type: EXPERIMENTAL
Intervention: Leukocyte count and CRP in the lowest tertile
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Leukocyte count and VCAM-1 in the lowest tertile
Number of subjects: 888
Study: 20535926

Group type: EXPERIMENTAL
Intervention: Simiao Xiaobi Decoction (SXD)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 120
Study: 18160247

Group type: EXPERIMENTAL
Intervention: Preoperative oxaliplatin (Ox)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Other chemotherapeutic agents (OC)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Surgery alone (SA)
Number of subjects: 173
Study: 15850123

Group type: EXPERIMENTAL
Intervention: Dynamic analysis
Number of subjects: 43

Group type: COMPARATOR
Intervention: Static analysis
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Static and dynamic models
Number of subjects: 43
Study: 14628178

Group type: EXPERIMENTAL
Intervention: Flupenthixol decanoate (10 mg, injected every second week for 24 weeks)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo (injected every second week for 24 weeks)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Flupenthixol decanoate (10 mg) in male patients
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Flupenthixol decanoate (10 mg) in female patients
Number of subjects: 281
Study: 10511763

Group type: EXPERIMENTAL
Intervention: Immediate stabilization with simple external fixation (group 2, 72 patients)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Conventional management (group 1, 40 patients)
Number of subjects: 112
Study: 7670929

Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon-alpha (2 x 10(6) IU/g)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Podophyllotoxin 0.5% in hydrophilic cream
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 60
Study: 2189027

Group type: EXPERIMENTAL
Intervention: Enalapril + Hydrochlorothiazide + Methyldopa
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard Triple Therapy (Hydrochlorothiazide + Propranolol + Hydralazine)
Number of subjects: 120
Study: 7005629

Group type: EXPERIMENTAL
Intervention: Levamisole (2.5 mg/kg orally on two consecutive days each week for 26 weeks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 33
Study: 31082942

Group type: EXPERIMENTAL
Intervention: Cytoreductive nephrectomy in combination with sunitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sunitinib alone
Number of subjects: 0
Study: 28486723

Group type: EXPERIMENTAL
Intervention: LASIK with the WaveLight Refractive Suite
Number of subjects: 96
Study: 26134359

Group type: EXPERIMENTAL
Intervention: (1→3)‐β‐d‐glucan (BDG) assay with cutoff positivity ≥80 pg/mL
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Candida albicans germ tube antibody (CAGTA) assay with cutoff positivity ≥1/160
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: BDG and CAGTA kinetics in IC patients treated with antifungals
Number of subjects: 107

Group type: COMPARATOR
Intervention: Confounding factors (amoxicillin–clavulanate, piperacillin–tazobactam treatments, recent surgery, Gram‐positive bloodstream infection, renal replacement therapy, enteral nutrition)
Number of subjects: 107
Study: 23660324

Group type: EXPERIMENTAL
Intervention: Catheter-direct thrombolysis (group B)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Peripheral venous thrombolysis (group A)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 86